Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Join the brightest minds in regulatory at the annual Regulatory Convergence. See the global regulatory community in action. Intensive workshops. Topical sessions. Meet ups with regulators. This is where it all comes together.
With so many global regulation changes, staying informed is a challenge. Join other regulatory professionals as you navigate the gray together.
Updated by a group of distinguished regulatory experts, this new edition is a must-have handbook for regulatory professionals at all levels.
In light of the COVID-19 pandemic, the RAC Board has elected to offer online testing with live online proctoring this summer.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.
Posted 09 December 2016 | By Zachary Brennan
Rep. Eric Swalwell (D-CA) on Friday sent a letter to US Food and Drug Administration (FDA) Commissioner Robert Califf seeking further assistance for start-up biotechnology companies in the Bay Area.
Swalwell said several companies have expressed their concerns on “the complexity and length of the regulatory process” that many do not have the resources to navigate. He also said the companies are seeking a local San Francisco Bay Area FDA office to provide face-to-face discussions on the regulations and science around drug development.
While recognizing that there are FDA offices in the region, Swalwell says they are primarily focused on regulating imports and “the lack of awareness of their existence shows more FDA outreach to the community is necessary.”
Letter
Tags: FDA in San Francisco, biotech start-ups
Regulatory Focus newsletters
All the biggest regulatory news and happenings.